Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Results from the DAYBREAK open-label extension study

Authors
Category Primary study
ConferenceMultiple Sclerosis Journal
Year 2019
This article has no abstract
Epistemonikos ID: 65f1fe7e8f869f95eb4da29b0c420a05ffe58745
First added on: Apr 29, 2026